分组1 - OrganiGram reported a quarterly loss of $0.20 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.01, marking an earnings surprise of -1,900% [1] - The company generated revenues of $56.91 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 7.1%, and showing a year-over-year increase from $32.77 million [2] - OrganiGram has not surpassed consensus EPS estimates in the last four quarters, but has topped revenue estimates three times during the same period [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - OrganiGram shares have increased by approximately 11.8% since the beginning of the year, compared to a 15.9% gain for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $51.11 million, with a breakeven forecast on revenues of $213.92 million for the current fiscal year [7] 分组3 - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 30% of over 250 Zacks industries, which may negatively impact stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5] - The estimate revisions trend for OrganiGram was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6]

Financial Data and Key Metrics Changes - In Q4, net revenue increased 79% to CAD 80.1 million from CAD 44.7 million in the same prior year period [16] - Full-year fiscal 2025 net revenue increased 62% to CAD 259.2 million from CAD 159.8 million in the prior year [16] - Adjusted gross profit for Q4 increased 85% to CAD 30.6 million versus CAD 16.5 million in Q4 last year [18] - Adjusted EBITDA set a company record in fiscal 2025, with Q4 adjusted EBITDA of CAD 9.8 million, an increase of 72% sequentially and 69% year-over-year [23] - The net loss for Q4 was CAD 38 million, compared to a net loss of CAD 5.4 million in the same prior year period [25] Business Line Data and Key Metrics Changes - The acquisition of Motif Labs contributed significantly to growth without market share dilution [4] - International sales reached a record CAD 26.3 million, a 171% increase versus the prior year [10][17] - The company achieved a 35% adjusted gross margin for the full year, a 100 basis point increase from last year [18] Market Data and Key Metrics Changes - The company holds the number one market position in Canada with an 11.9% market share in fiscal 2025 [7] - Market share in New Brunswick reached 34.2%, 23.7% in Newfoundland, 14.9% in Saskatchewan, and 12.2% in Nova Scotia [8] - The company experienced a temporary market share impact in Q1 due to a strike affecting large LPs in British Columbia [10] Company Strategy and Development Direction - The company aims to increase the margin profile of its domestic product mix while optimizing operational footprint for capacity and throughput [9] - Plans to launch new products, including coated infused pre-rolls and beverages, are in place to meet evolving consumer needs [9] - The company is focused on disciplined execution and sustainable growth, with an emphasis on margin expansion and international growth [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth supported by a stronger platform and expanding international opportunities [29] - The company is monitoring regulatory changes in the U.S. that could impact its business but does not expect a material adverse economic impact [12] - Management anticipates strong net revenue growth exceeding CAD 300 million in fiscal 2026, along with further improvements in adjusted gross margin and adjusted EBITDA [27] Other Important Information - The company received a CAD 2 million grant from Opportunities New Brunswick to support facility enhancements [6] - The Jupiter Fund currently has CAD 59 million available for deployment to leverage opportunities in markets outside of Canada [13] - The company is awaiting a determination on its EU-GMP application, which could positively impact its international business [12] Q&A Session Summary Question: International growth expectations and supply-demand dynamics - Management indicated that they are starting to realize increased capacity and are well-positioned for fiscal 2026, particularly in Germany [34] Question: Gross margin expectations for fiscal 2026 - Management expects gross margins to improve, driven by operational improvements and synergies from the Motif acquisition [38] Question: Margin improvement sources - The majority of margin improvement is expected to come from operational improvements in cultivation rather than solely from Motif synergies [48] Question: CapEx plans for the next year - The company plans to keep capital expenditures modest for fiscal 2026, with expectations to spend less than CAD 10 million [49]

Financial Data and Key Metrics Changes - In Q4, net revenue increased 79% to CAD 80.1 million from CAD 44.7 million in the same prior year period [15] - Full-year fiscal 2025 net revenue increased 62% to CAD 259.2 million from CAD 159.8 million in the prior year [15] - Adjusted gross profit for Q4 increased 85% to CAD 30.6 million versus CAD 16.5 million in Q4 last year [16] - Adjusted EBITDA set a company record in fiscal 2025, with Q4 adjusted EBITDA of CAD 9.8 million, an increase of 72% sequentially and 69% year-over-year [20] - The net loss for Q4 was CAD 38 million, compared to a net loss of CAD 5.4 million in the same prior year period [22] Business Line Data and Key Metrics Changes - The acquisition of Motif Labs contributed significantly to growth without market share dilution [4] - The company achieved record international sales of CAD 26.3 million in fiscal 2025, a 171% increase versus the prior year [10] - Adjusted gross margin in Q4 rose by 400 basis points over Q3 to 38% [17] Market Data and Key Metrics Changes - Organigram holds the number one market position in Canada with 11.9% market share in fiscal 2025 [6] - The company ranked first in Ontario, British Columbia, and Alberta, and fourth in Quebec [7] - Market share in New Brunswick reached 34.2%, Newfoundland 23.7%, Saskatchewan 14.9%, and Nova Scotia 12.2% [7] Company Strategy and Development Direction - The company aims to increase the margin profile of its domestic product mix while optimizing operational footprint for capacity and throughput [9] - Plans to launch new products, including coated infused pre-rolls and beverages, to meet evolving consumer needs [9] - The focus on international expansion includes launching branded vapes and gummies in Australia [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth supported by a stronger platform and expanding international opportunities [26] - The company anticipates strong net revenue growth exceeding CAD 300 million in fiscal 2026 [24] - Management is monitoring U.S. regulatory changes that could impact the hemp-derived THC market but does not expect a material adverse economic impact [12] Other Important Information - The company received a CAD 2 million grant from Opportunities New Brunswick to support facility enhancements [6] - The Jupiter Fund currently has CAD 59 million available for deployment to leverage opportunities in markets outside of Canada [13] - The company is awaiting a determination on its EU-GMP application submitted in October 2025 [12] Q&A Session Summary Question: International growth expectations and supply-demand dynamics - Management indicated that they are starting to realize increased capacity and are well-positioned for fiscal 2026, particularly in Germany [32] Question: Gross margin expectations for fiscal 2026 - Management expects continued improvement in gross margin driven by operational improvements and synergies from the Motif acquisition [36] Question: Contribution of Motif synergies versus cultivation improvements to margin improvement - Management stated that the majority of margin improvement will come from operational improvements in cultivation rather than solely from Motif synergies [46] Question: Capital expenditure plans for the next year - Management plans to keep capital expenditures modest for fiscal 2026, expecting to spend less than CAD 10 million [47]

Investor Presentation September 30, 2025 CAUTIONARY STATEMENT This document is current as of September 30, 2025, except where otherwise stated. The information contained in this presentation is provided by Organigram Global Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be reli ...

Core Insights - Organigram Global Inc, Canada's leading recreational cannabis company, reported record financial results for the fourth quarter and fiscal year ending September 30, 2025, highlighting significant growth in revenue and market share [2][4]. Fiscal 2025 Financial Highlights - Gross revenue reached $403.0 million, a 63% increase year-over-year, while net revenue was $259.2 million, up 62% from the previous year [4][6]. - Adjusted EBITDA increased by 160% to $21.9 million, driven by higher recreational cannabis revenue and improved gross margins [4][6]. - The company maintained a 11.9% market share in the Canadian recreational cannabis market [4][6]. Fourth Quarter 2025 Financial Overview - In Q4, gross revenue was $123.3 million, a 76% increase year-over-year, with net revenue rising 79% to $80.1 million [4][6]. - Adjusted gross margin for Q4 was $30.6 million, representing 38% of net revenue, compared to 37% in Q4 Fiscal 2024 [4][6]. - The net loss for Q4 was $38.0 million, a significant increase from a loss of $5.4 million in the same quarter last year, primarily due to non-cash changes in fair value [4][6]. Strategic Initiatives and Acquisitions - The company expanded its capabilities through acquisitions, including Motif Labs Ltd., enhancing its extraction capabilities and market presence [2][4]. - Organigram launched its Fast Acting Soluble Technology (FAST) and entered the U.S. cannabinoid beverages market through the acquisition of Collective Project Limited [4][12]. - The company is focused on operational scale, intellectual property, and market access to support future growth [2][4]. International Growth - Record international revenue reached $26.3 million, a 173% increase year-over-year, reflecting the company's expanding global footprint [4][12]. - The company completed its EU-GMP audit and is awaiting certification confirmation, which will facilitate further international expansion [12][4]. Balance Sheet and Liquidity - As of September 30, 2025, the company had cash, restricted cash, and short-term investments totaling $84.4 million, down from $133.4 million the previous year [9][10]. - Total assets increased by 37% to $562.2 million, while total liabilities rose by 109% to $213.1 million [10][9]. Future Outlook - The company anticipates strong revenue growth in Fiscal 2026, with net revenue expected to exceed $300 million, supported by increasing domestic and international demand [7][4].

Group 1: Canadian Tech Sector - Celestica Inc. shares fell 12.92% due to "AI skepticism," impacting the overall index negatively [1] Group 2: Canadian Cannabis Companies - Tilray Brands Inc. shares increased by 44.35%, Canopy Growth Corp. shares rose by 52.87%, Aurora Cannabis Inc. shares were up 19.04%, and Organigram Global Inc. shares increased by 16.81% following reports of potential easing of federal restrictions on cannabis by U.S. President Donald Trump [2] - The aggressive legalization in the U.S. could revitalize Canadian cannabis stocks, which had previously seen significant declines [2] Group 3: Canadian Economic Indicators - Investors are anticipating November inflation data, with a consensus forecast of 2.3% headline inflation, which will provide insights into the Canadian economy's health [3] - The Bank of Canada policy rate is currently at 2.25% [3] Group 4: U.S. Market Performance - Broadcom's shares dropped 11.4% despite reporting stronger-than-expected profits, contributing to market concerns about the AI sector [4] - Oracle's shares fell nearly 11% after reporting better-than-expected profits, raising fears about high valuations in the AI market [5] - The S&P 500 index was notably affected by declines in Broadcom and Nvidia, with Oracle's results causing disappointment among investors [5] Group 5: Market Indices and Commodities - The Dow Jones industrial average decreased by 245.96 points, the S&P 500 index fell by 73.59 points, and the Nasdaq composite dropped by 398.69 points [6] - The Canadian dollar traded at 72.63 cents US, and crude oil prices fell by 16 cents to US$57.44 per barrel, while gold prices increased by US$15.30 to US$4,328.30 per ounce [6]

Core Viewpoint - The stock prices of major cannabis companies surged significantly following reports of President Trump's plans to relax federal regulations on marijuana, with notable increases in premarket trading [1][2]. Group 1: Stock Price Movements - Tilray Brands (NASDAQ:TLRY) saw a price increase of 34.88%, while Canopy Growth (NASDAQ:CGC) rose by 27.46% in premarket trading [1]. - Other companies also experienced substantial gains: Aurora Cannabis Inc. (NASDAQ:ACB) surged 20%, Cronos Group Inc. (NASDAQ:CRON) gained 19%, Organigram Global Inc. (NASDAQ:OGI) rose 12%, and SNDL Inc. (NASDAQ:SNDL) increased by 34.7% [1]. Group 2: Regulatory Changes - The surge in stock prices was attributed to news that Trump plans to instruct federal agencies to reclassify marijuana as a Schedule III drug, which would change its regulatory status [2][3]. - This reclassification would subject cannabis companies to different tax regulations, potentially attracting more investments and placing marijuana in the same category as substances like steroids and Tylenol with codeine [3]. Group 3: Historical Context - Trump had previously hinted at this reclassification in August, indicating a consistent approach towards cannabis regulation [3]. - The anticipated change is expected to occur early next year, moving marijuana from a category that includes heroin to a lower tier for less dangerous substances [4].

Core Viewpoint - Organigram Global Inc., Canada's leading cannabis company by market share, is set to report its earnings for the fourth quarter of fiscal 2025 on December 16, 2025, before market opening [1]. Company Overview - Organigram Global Inc. is listed on NASDAQ and TSX, with subsidiaries including Organigram Inc., a licensed cultivator and processor [3]. - The company has expanded into the US and Canadian cannabinoid beverages markets through its acquisition of Collective Project Limited [3]. - Organigram focuses on producing high-quality cannabis for adult recreational consumers and aims to develop international business partnerships to enhance its global presence [4]. - The company has a diverse portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, and SHRED, among others [4]. - Organigram operates multiple facilities across Canada, including locations in Moncton, New Brunswick, and Lac-Supérieur, Quebec, as well as a dedicated edibles manufacturing facility in Winnipeg, Manitoba [4]. Operational Facilities - The Aylmer facility is equipped with advanced extraction capabilities and is optimized for formulation refinement and pre-roll production [4]. - The London facility focuses on labeling, packaging, and national fulfillment [4].

Core Viewpoint - Organigram Global Inc. has appointed James Yamanaka as the new Chief Executive Officer, effective on or about January 15, 2026, to lead the company in its growth and international expansion efforts [1][4]. Group 1: Leadership Appointment - James Yamanaka, previously Global Head of Strategy at British American Tobacco, brings over 20 years of experience in strategy and general management [2][3]. - Yamanaka's track record includes achieving record market share in Japan and transforming BAT's Northern Europe Area for sustainable growth [3]. - Peter Amirault will serve as executive chair on an interim basis until Yamanaka assumes the CEO role [4]. Group 2: Strategic Vision - Yamanaka expressed enthusiasm for the challenge, highlighting Organigram's position as Canada's number one recreational cannabis company by market share and its potential to become a global leader in the cannabis industry [4]. - The company aims to build an international presence based on high-quality products, trusted brands, and a commitment to innovation [4]. Group 3: Educational Background - James Yamanaka holds a BA in Political Science and Economics from UC San Diego, an M.S. in Foreign Service from Georgetown University, and an MBA from London Business School [4].

Core Insights - 420 Investor was launched in 2013, coinciding with Colorado's legalization of cannabis for adult use, and has now transitioned its services to Seeking Alpha [1] - The service has historically provided extensive coverage of the cannabis sector, including model portfolios, videos, and written materials to assist investors in understanding cannabis stocks [1] - The leader of 420 Investor, Alan Brochstein, has been focused on Canadian licensed producers (LPs) since their inception and currently maintains a model portfolio with a 19.4% exposure in two cannabis stocks [1] Company Overview - Alan Brochstein, CFA, is recognized as one of the first investment professionals dedicated to the cannabis industry, starting his career in the securities industry in 1986 [1] - He founded AB Analytical Services in 2007 to offer independent consulting to registered investment advisors and has been managing New Cannabis Ventures since 2015, which provides financial information relevant to the cannabis industry [1] - The investing group 420 Investor, which Brochstein has led since 2013, closely monitors 20 cannabis stocks, providing timely investment news, earnings report previews, and post-report analyses [1] Service Features - The 420 Investor group includes a model portfolio, 10 weekly videos featuring chart analysis, three summary pieces each week, a monthly newsletter, and a chat feature for investor inquiries [1]